Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14
Lasa Supergenerics acquires Harishree Aromatics - The Pharma Times | Pharma & Health Care News Portal
Categories: Health Care

Lasa Supergenerics acquires Harishree Aromatics

Chennai, February 28, 2020: Veterinary API major, Lasa Supergenerics Limited recently announced its acquisition of Harishree Aromatics And Chemicals Private Limited which is in the manufacturing of Veterinary API & Other Pharmaceuticals Intermediates.

In addition to the takeover of the manufacturing unit along with all other assets and liabilities whereas transferor is a debt free company, the amalgamation and consolidation will result in an increase in market share, product and services diversification, combined pool of reserves, investments and other assets giving it a competitive edge over its listed and unlisted peers

While the deal size has not been disclosed, the corporate announcement uploaded on the stock exchanges stated that on the scheme becoming effective shareholders of Harishree will be entitled to 1000 fully paid up shares of Lasa for every 35 equity shares held

Commenting on the acquisition, Dr. Omkar Herlekar, Chairman– Lasa Supergenerics Limited, said “This acquisition has been a strategic decision to restructure our current potential and a forward integrate. The amalgamation of both the entities stands to extract synergistic benefits, economies of scale, better cash flow management, optimisation of borrowing costs resulting in better financial and operational efficiencies and better shareholder value”

The company recently announced the third quarter and nine months ended results where it turned net positive. It declared revenue of Rs. 39.29 cr, EBITA of Rs. 8.16 cr which was up by 8.7%, EPS of Rs.0.89 as compared to a negative 2.31 and a PAT of Rs 2.57 cr against a loss of Rs.5.28 cr compared to the previous quarter. The company is working towards bringing down the finance costs and the working capital cycle.

The share price has been hitting new 52 week high record post Q3FY20 results and acquisition of new entity. The stock has achieved upper circuit for last six consecutive days with a total turnover of approx 32,90,089 and a 100% quantity deliverable.  The investors are cheering the inorganic growth strategy of the company and hope the trajectory will continue and will help to increase the value of the shareholders.

Corporate Comm India (CCI Newswire)

The Pharma Times News Bureau

Recent Posts

Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT);

Achieves significant advancement in Cancer Treatment to Enhance Quality of Life  As per the National…

17 hours ago

Two Complex Robotic Kidney Transplant Surgeries Successfully Performed at Fortis Hospital Bannerghatta Road

-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…

2 days ago

On International Nurses Day, American Oncology Institute (AOI) launches #TheExtraordinaryCareGiver Campaign as Tribute to Oncology Nurses

Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…

3 days ago

SOCC Unveils A New Era In Paediatric Care: Second Opinion Online Consultations For Children

Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…

6 days ago

India’s First Lady Surgeon Trained in Robotic Breast Surgery Performs Karnataka’s 1st Robotic Nipple Sparing Mastectomy

Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…

1 week ago

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

2 weeks ago

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 5420